Follow
Andreas Behren
Andreas Behren
Olivia Newton-John Cancer Research Institute
Verified email at onjcri.org.au - Homepage
Title
Cited by
Cited by
Year
Pan-cancer analysis of whole genomes.
S Hirano, L Yang, M Juul, CA Purdie, BP O'Neill, R Kabbe, ...
Nature 578 (DKFZ-2020-01051), 82-93, 2020
1715*2020
Whole-genome landscapes of major melanoma subtypes
NK Hayward, JS Wilmott, N Waddell, PA Johansson, MA Field, K Nones, ...
Nature 545 (7653), 175-180, 2017
12862017
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
ML Burr, CE Sparbier, YC Chan, JC Williamson, K Woods, PA Beavis, ...
Nature 549 (7670), 101-105, 2017
7512017
Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells
M Rigau, S Ostrouska, TS Fulford, DN Johnson, K Woods, Z Ruan, ...
Science 367 (6478), 2020
3372020
A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients
J Cursons, F Souza-Fonseca-Guimaraes, M Foroutan, A Anderson, ...
Cancer immunology research 7 (7), 1162-1174, 2019
2232019
Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
SCH Tsao, J Weiss, C Hudson, C Christophi, J Cebon, A Behren, ...
Scientific reports 5 (1), 1-11, 2015
1912015
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial
O Klein, D Kee, A Nagrial, B Markman, C Underhill, M Michael, L Jackett, ...
Jama Oncology 6 (9), 1405-1409, 2020
1842020
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
EF Lee, TJ Harris, S Tran, M Evangelista, S Arulananda, T John, ...
Cell Death & Disease 10 (5), 342, 2019
1602019
BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage
VJ Mar, SQ Wong, J Li, RA Scolyer, C McLean, AT Papenfuss, RW Tothill, ...
Clinical Cancer Research 19 (17), 4589-4598, 2013
1542013
Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma
A Jayachandran, M Anaka, P Prithviraj, C Hudson, SJ McKeown, PH Lo, ...
Oncotarget 5 (14), 5782, 2014
1402014
Immunotherapy of Ipilimumab and Nivolumab in patients with advanced neuroendocrine tumours: a subgroup analysis of the CA209-538 clinical trial for rare cancers
O Klein, D Kee, B Markman, M Michael, CR Underhill, MS Carlino, ...
Clinical Cancer Research, 2020
1382020
Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma
N Jacquelot, C Seillet, M Wang, A Pizzolla, Y Liao, S Hediyeh-Zadeh, ...
Nature immunology 22 (7), 851-864, 2021
1282021
Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma
J Wang, A Wuethrich, AAI Sina, RE Lane, LL Lin, Y Wang, J Cebon, ...
Science Advances 6 (9), eaax3223, 2020
1232020
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma
H Halse, AJ Colebatch, P Petrone, MA Henderson, JK Mills, H Snow, ...
Scientific reports 8 (1), 1-14, 2018
1112018
Characterising the phenotypic evolution of circulating tumour cells during treatment
SCH Tsao, J Wang, Y Wang, A Behren, J Cebon, M Trau
Nature communications 9 (1), 1482, 2018
1042018
A digital single-molecule nanopillar SERS platform for predicting and monitoring immune toxicities in immunotherapy
J Li, A Wuethrich, AAI Sina, HH Cheng, Y Wang, A Behren, ...
Nature communications 12 (1), 1087, 2021
832021
Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ
LJ Vella, A Behren, B Coleman, DW Greening, AF Hill, J Cebon
Neoplasia 19 (11), 932-940, 2017
642017
PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
CSA Tutuka, MC Andrews, JM Mariadason, P Ioannidis, C Hudson, ...
Molecular Cancer 16 (1), 112, 2017
622017
Autoantibodies may predict immune-related toxicity: results from a phase I study of Intralesional Bacillus Calmette-Guerin followed by ipilimumab in patients with advanced …
J Da Gama Duarte, S Parakh, MC Andrews, K Woods, A Pasam, C Tutuka, ...
Frontiers in Immunology 9, 411, 2018
602018
FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.
BS Tan, M Anaka, S Deb, C Freyer, LM Ebert, AC Chueh, S Al-Obaidi, ...
Oncotarget 5 (1), 264, 2014
602014
The system can't perform the operation now. Try again later.
Articles 1–20